Table 4 Change from baseline in patient reported outcomes by EULAR response states in the abatacept treatment group
Patient reported outcomeEULAR
GoodModerateNone
(n = 34)(n = 69)(n = 200)
Activity limitation−9.2 (11.8)−8.3 (13.4)−3.1 (11.1)
Fatigue−39.9 (31.7)−28.1 (33.1)−8.2 (25.4)
Sleep quality−9.9 (21.2)−14.0 (15.8)−4.7 (15.2)
SF-36 Physical functioning11.9 (8.9)7.2 (10.4)1.7 (9.8)
SF-36 Role-physical17.3 (10.0)8.4 (10.9)1.5 (8.6)
SF-36 Bodily pain17.4 (11.6)10.1 (11.1)3.8 (8.1)
SF-36 General health9.7 (8.2)5.0 (8.8)1.0 (7.3)
SF-36 Vitality11.4 (11.5)9.2 (10.6)3.0 (9.8)
SF-36 Social functioning12.9 (14.6)9.4 (10.3)2.4 (11.0)
SF-36 Role-emotional12.7 (15.5)7.6 (15.3)3.0 (15.6)
SF-36 Mental health8.0 (11.1)4.3 (9.4)1.8 (9.8)
SF-36 Physical component15.1 (8.4)8.7 (11.0)1.8 (7.7)
SF-36 Mental component8.9 (12.5)5.7 (10.7)2.5 (11.1)
  • Values are mean (SD).

  • EULAR, European League against Rheumatism; SF-36, short form 36 item health survey.